THERAPEUTICS SYMPOSIUM

1 Bressler NM. Treatment of age-related macular degneration with photodynamic therapy (TAP) study group. Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: two-year results of 2 randomized clinical trials – tap report 2. Arch Ophthalmol 2001; 119:198–207.

2Age-related Eye Disease Study Research Group. A randomized, placebo-controlled, clinical trial of high-dose supplementation with vitamins C and E, beta carotene, and zinc for age-related macular degeneration and vision loss: AREDS report no. 8. Arch Ophthalmol 2001; 119:1417–36.

3 Leyland M Zinicola E. Multifocal versus monofocal intraocular lenses after cataract extraction (Cochrane Review). Cochrane Database Syst Rev 2001; 3:CD003169.

4World Health Organisation. Assessment of fracture risk and its application to screening for postmenopausal osteoporosis. Report of a WHO Study Group. World Health Organ Tech Rep Ser 1994; 843:1–129.

5 Peat ID S Healy Reid DM Steroid induced osteoporosis: an opportunity for prevention? Ann Rheum Dis 1995; 54:66–8.

6National Institute for Clinical Effectiveness. Guidance on the use of donepezil, rivastigmine and galantamine for the treatment of Alzheimer’s disease. Technology Appraisal Guidance No. 19. London: National Institute of Clinical Excellence; 2001.

7 Thomson FC K Fraser Kelly J Drug treatment of dementia. Hosp Pharm 2001; 8:41–9.

8 Boland EA M Grey Oesterle A Continuous subcutaneous insulin infusion. A new way to lower risk of severe hypoglycemia, improve metabolic control, and enhance coping in adolescents with type 1 diabetes. Diabetes Care 1999; 22:1779–84.

9 Mudaliar SR FA Lindberg Joyce M Insulin aspart (B28 asp-insulin): a fast-acting analog of human insulin: absorption kinetics and action profile compared with regular human insulin in healthy nondiabetic subjects. Diabetes Care 1999; 22:1501–6.

10 Lepore M S Pampanelli Fanelli C Pharmacokinetics and pharmacodynamics of subcutaneous injection of longacting human insulin analog glargine, NPH insulin, and ultralente human insulin and continuous subcutaneous infusion of insulin lispro. Diabetes 2000; 49:2142–8.

11 Skyler JS WT Cefalu Kourides IA Efficacy of inhaled human insulin in type 1 diabetes mellitus: a randomised proof-of-concept study. Lancet 2001; 357:331–5.

12 Shapiro AM JR Lakey Ryan EA Islet transplantation in seven patients with type 1 diabetes mellitus using a glucocorticoid-free immunosuppressive regimen. N Engl J Med 2000; 343:230–8.

13Scottish Intercollegiate Guidelines Network. Management of diabetes. A national clinical guideline. Edinburgh: SIGN;1999 (SIGN Publication no. 55).

14 Wolffenbuttel BH R Gomis Squatrito S Addition of low-dose rosiglitazone to sulphonylurea therapy improves glycaemic control in Type 2 diabetic patients. Diabet Med 2000; 17:40–7.

15 Goldstein DJ. Beneficial health effects of modest weight loss. Int J Obesity 1992; 16:397–415.

16Scottish Intercollegiate Guidelines Network. Obesity in Scotland: integrating prevention with weight mangement. A national clinical guideline. Edinburgh: SIGN;1996 (SIGN Publication no. 8).

17Clinical management of overweight and obese patients: with particular reference to the use of drugs. London: Royal College of Physicians of London; 1998.

18 Urquhart J De Klerk E. Contending paradigms for the interpretation of data on patient compliance with therapeutic drug regimens. Stat Med 1998; 17:251–67.

19 Urquhart J. Internal medicine in the 21st century: controlled drug delivery: therapeutic and pharmacological aspects. J Intern Med 2000; 248:357–76.

20 Burnier M MP Schneider Chiolero A Electronic compliance monitoring in resistant hypertension: the basis for rational therapeutic decisions. J Hypertens 2001; 19:335–41.

21 Routledge P. 150 years of pharmacovigilance. Lancet 1998; 351:1200–1.

22 Stephens MDB J Talbot Routledge PA. Detection of new adverse drug reactions: pharmacovigilance. Fourth edition. London: Macmillan;1998.

23 Houghton J F Woods Davis S Community reporting of suspected ADRs (2). Attitudes of community pharmacists and general practitioners in Wales. Pharm J 1999; 263:788–91.

24 Ramachandran VS Hirstein W. The perception of phantom limbs. The D.O. Hebb lecture. Brain 1998; 121:1603–30.

25 Gelband CH MJ Katovich Raizada MK. Current perspectives on the use of gene therapy for hypertension. Circ Res 2000; 87:1118–22.

26 Pachori AS MJ Huentelman Francis SC The future of hypertension therapy: sense, antisense, or nonsense? Hypertension 2001; 37:357–64.

27 Pachori AS H Wang Gelband CH Inability to induce hypertension in normotensive rat expressing AT(1) receptor antisense. Circ Res 2000; 86:1167–72.

28 Elliott MJ RN Maini Feldmann M Treatment of rheumatoid arthritis with chimeric monoclonal antibodies to tumor necrosis factor alpha. Arthritis Rheum 1993; 36:1681–90.

29 Elliott MJ RN Maini Feldmann M Randomised doubleblind comparison of chimeric monoclonal antibody to tumour necrosis factor alpha (cA2) versus placebo in rheumatoid arthritis. Lancet 1994; 344:1105–10.

30 Moreland LW SW Baumgartner Schiff MH Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor receptor (p75)-Fc fusion protein. N Engl J Med 1997; 337:141–7.

31 Maini R EW St Clair Breedveld F Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group. Lancet 1999; 354:1932–9.

32 Alton EW M Stern Farley R Cationic lipid-mediated CFTR gene transfer to the lungs and nose of patients with cystic fibrosis: a double-blind placebo-controlled trial. Lancet 1999; 353:947–54.

33 Stern M NJ Caplen Browning JE The effect of mucolytic agents on gene transfer across a CF sputum barrier in vitro. Gene Ther 1998; 5:91–8.

34 Davies JC M Stern Dewar A CFTR gene transfer reduces the binding of Pseudomonas aeruginosa to cystic fibrosis respiratory epithelium. Am J Respir Cell Mol Biol 1997; 16:657–63.

35 Yonemitsu Y C Kitson Ferrari S Efficient gene transfer to airway epithelium using recombinant Sendai virus. Nat Biotechnol 2000; 18:970–3.

36 Holmes D P Fitzgerald Goldberg S The PRESTO (Prevention of restenosis with tranilast and its outcomes) protocol: a double-blind, placebo-controlled trial. Am Heart J 2000; 139:23–31.

37 Bosma PJ JR Chowdhury Bakker C The genetic basis of the reduced expression of bilirubin UDP-glucuronosyltransferase 1 in Gilbert’s syndrome. N Engl J Med 1995; 333:1171–5.